<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03182907</url>
  </required_header>
  <id_info>
    <org_study_id>6072-001</org_study_id>
    <secondary_id>2017-000070-11</secondary_id>
    <nct_id>NCT03182907</nct_id>
  </id_info>
  <brief_title>Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)</brief_title>
  <acronym>MODIFY III</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. Difficile Toxin B) in Children Aged 1 to &lt;18 Years Receiving Antibacterial Drug Treatment for C. Difficile Infection (MODIFY III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the pharmacokinetics (PK), safety, and
      tolerability of bezlotoxumab in children aged 1 to &lt;18 years of age with a confirmed
      diagnosis of Clostridium difficile infection (CDI) who are receiving antibacterial drug
      treatment. The primary hypothesis is that the area under the concentration-time curve from 0
      to infinity (AUC0-inf) of bezlotoxumab after treatment of pediatric participants with
      bezlotoxumab is similar when compared to the AUC0-inf of bezlotoxumab after treatment of
      adults with bezlotoxumab,
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">May 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration time curve of bezlotoxumab</measure>
    <time_frame>Day 1 (2 hrs after infusion), Days 10, 29, 57, and 85</time_frame>
    <description>Area under the concentration time curve from time 0 to infinity (AUC0-inf) of serum bezlotoxumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>Percentage of participants experiencing AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuing medication</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of participants discontinuing study medication due to an AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clostridium difficile infection (CDI) recurrence</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Percentage of participants who have a CDI recurrence within 12 weeks of study medication infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained clinical response</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Percentage of participants with sustained clinical response within 12 weeks of study medication infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDI recurrence and sustained clinical response</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Percentage of participants who have a CDI recurrence and who achieve sustained clinical response within 12 weeks of study medication infusion in participants at high risk of CDI recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion-related reactions</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Percentage of participants experiencing 1 or more infusion-related reactions within 24 hours following the start of study medication infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive antibodies to bezlotoxumab</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Percentage of participants with treatment-emergent positive antibodies to bezlotoxumab in serum through 12 weeks following a single dose of bezlotoxumab.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Bezlotoxumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bezlotoxumab</intervention_name>
    <description>A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.</description>
    <arm_group_label>Bezlotoxumab</arm_group_label>
    <other_name>MK-6072</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At screening has suspected or confirmed CDI, and is receiving or is planning to
             receive a 10- to 21-day course of antibacterial drug treatment for CDI

          -  At study infusion has a diagnosis of CDI confirmed by a diagnostic assay which detects
             the presence of C. difficile toxin in stool, and is still receiving antibacterial drug
             treatment for CDI.

          -  Female is not pregnant, and not breastfeeding; but if of childbearing potential agrees
             to follow contraceptive guidance during the treatment period and for at least 12 weeks
             after the last dose of study treatment

          -  Participant and/or parent or caregiver must be able to read, understand, and complete
             the daily diary

        Exclusion Criteria:

          -  Has an uncontrolled chronic diarrheal illness

          -  At randomization, their planned course of antibacterial drug treatment for CDI is
             longer than 21 days

          -  At screening has received any listed prohibited prior and concomitant treatments and
             procedures

          -  Has previously participated in this study, has previously received bezlotoxumab, has
             received an experimental monoclonal antibody against C. difficile toxin B, or has
             received a vaccine directed against C. difficile or its toxins.

          -  Has received an investigational study agent within the previous 30 days, or is
             currently participating in or scheduled to participate in any other clinical study
             with an investigational agent during the 12-week study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital - Los Angeles ( Site 0021)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-361-5047</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Colorado ( Site 0013)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-777-8591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago ( Site 0019)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-702-1665</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Hospital ( Site 0007)</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>225-765-4365</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Rubenstein Child Health Building ( Site 0034)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-614-2949</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University ( Site 0037)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-747-5128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/ MSCHONY ( Site 0042)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-342-3647</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical Center, University Hospital ( Site 0027)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>315-464-7353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center ( Site 0029)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-983-6925</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of San Antonio ( Site 0009)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-704-4708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center ( Site 0001)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-581-6631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens Hospital ( Site 0028)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-884-5086</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno ( Site 2000)</name>
      <address>
        <city>Brno</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420532234126</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen ( Site 2001)</name>
      <address>
        <city>Plzen Lochotin</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420377104330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>2. LF UK a FN Motol ( Site 2003)</name>
      <address>
        <city>Praha 5</city>
        <zip>Prague 6</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420224436568</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet ( Site 2202)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3614558517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem II. sz. Gyermekgyogyaszati Klinika ( Site 2201)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3612151380</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 2200)</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3662545330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland universitetssykehus ( Site 1501)</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4755975200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo universitetssykehus ( Site 1500)</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4723074593</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno Zakazny ( Site 2404)</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48523255605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 2405)</name>
      <address>
        <city>Dziekanow Lesny</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48227657153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im. dr W. Bieganskiego w Lodzi ( Site 2400)</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48422516104</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 1603)</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351225084000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Academic Hospital ( Site 2602)</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27119330270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sefako Makgatho Health Sciences University ( Site 2603)</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27125215633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan de Deu ( Site 1704)</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915035900235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus ( Site 1701)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915035900235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 1703)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915035900235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio ( Site 1705)</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955013704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barncancercentrum ( Site 1801)</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46313436082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ITCC Barnokologen Astrid Lindgrens Barnsjukhus NKS ( Site 1800)</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46722214431</phone>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

